Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment
Status:
NOT_YET_RECRUITING
Trial end date:
2026-11-04
Target enrollment:
Participant gender:
Summary
This is a multicenter, single-dose, open-label, parallel Phase 1 clinical study to evaluate the PK profile, safety, and tolerability of GZR4 Injection in subjects with mild, moderate, and severe hepatic impairment.